RedHill Biopharma (RDHL) Non Operating Investment Income (2015 - 2019)
RedHill Biopharma (RDHL) posted quarterly Non Operating Investment Income of -$8000.0 for Q4 2019, up 99.64% year-over-year from -$4007.3 in Q4 2018, and down 60.0% quarter-over-quarter from -$5000.0 in Q3 2019.
RedHill Biopharma (RDHL) Non Operating Investment Income (2015 - 2019) Analysis & Trends
RedHill Biopharma (RDHL) has reported Non Operating Investment Income for 5 consecutive years, with -$8000.0 the latest figure, recorded in Q4 2019.
- In Q4 2019, Non Operating Investment Income rose 99.64% year-over-year to -$8000.0; the TTM figure through Dec 2019 stood at -$344000.0 (down 230.77% YoY), while the FY2019 annual figure was -$344000.0, down 230.77% from the prior year.
- Non Operating Investment Income eased to -$8000.0 in Q4 2019 per RDHL's latest filing, from -$5000.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $1.7 million in Q3 2017 and bottomed at -$3.9 million in Q4 2017.
- Historically, Non Operating Investment Income has averaged -$408750.0 across 5 years, with a median of -$183500.0 in 2015.
- Annual changes were most pronounced in 2017 — Non Operating Investment Income tumbled 527.86% — and 2019, when it jumped 2046.0%.
- RedHill Biopharma's Non Operating Investment Income stood at -$166000.0 in 2015, then tumbled by 515.66% to -$1.0 million in 2016, then tumbled by 277.59% to -$3.9 million in 2017, then soared by 43.2% to -$2.2 million in 2018, then jumped by 99.64% to -$8000.0 in 2019.
- Business Quant data shows RDHL's Non Operating Investment Income at -$8000.0 in Q4 2019, -$5000.0 in Q3 2019, and -$1.3 million in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | RedHill Biopharma | 2.05 Bn | 2.05 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -8,000.00 |
| Dec 31, 2019 | -8,000.00 |
| Sep 30, 2019 | -5,000.00 |
| Sep 30, 2019 | -5,000.00 |
| Jun 30, 2019 | -1.30 Mn |
| Jun 30, 2019 | -1.30 Mn |
| Mar 31, 2019 | 973,000.00 |
| Mar 31, 2019 | 973,000.00 |
| Dec 31, 2018 | -2.19 Mn |
| Dec 31, 2018 | -2.19 Mn |
| Sep 30, 2018 | 471,000.00 |
| Sep 30, 2018 | 471,000.00 |
| Jun 30, 2018 | 1.67 Mn |
| Jun 30, 2018 | 1.67 Mn |
| Mar 31, 2018 | -50,000.00 |
| Mar 31, 2018 | -50,000.00 |
| Dec 31, 2017 | -3.86 Mn |
| Dec 31, 2017 | -3.86 Mn |
| Sep 30, 2017 | 1.69 Mn |
| Sep 30, 2017 | 1.69 Mn |